Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,098.00
Bid: 12,098.00
Ask: 12,100.00
Change: 70.00 (0.58%)
Spread: 2.00 (0.017%)
Open: 12,036.00
High: 12,114.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-AstraZeneca, U.S. agree 500,000 more supplies of COVID-19 antibody cocktail

Tue, 16th Mar 2021 07:23

* Extended U.S. deal for $205 mln, total value now at $726
mln

* Overall supply deal contingent on approval of treatment,
AZD7442

* Deal comes as AZ grapples with COVID-19 vaccine
suspensions
(Writes through with new details, background)

By Pushkala Aripaka

March 16 (Reuters) - AstraZeneca will supply up to
half a million extra doses of its experimental antibody-based
COVID-19 combination therapy to the United States, in a bright
spot for the company after more governments suspended use of its
vaccine over safety fears.

The antibody therapy, which has yet to be approved by U.S.
regulators, is designed to treat the disease rather than prevent
it like the vaccine, which several countries have stopped using
while reports of blood clots in some people are investigated.

The Anglo-Swedish drugmaker said on Tuesday the $205 million
U.S. extension for 500,000 antibody doses builds on a contract
agreed with government agencies in October for initial supplies
of 200,000 doses of the antibody cocktail, AZD7442.

The treatment is a combination of two monoclonal antibodies,
London-listed AstraZeneca said, adding that the new agreement is
contingent on an emergency use approval by the U.S. Food and
Drug Administration.

"The US Government's support is critical in helping
accelerate the development of AZD7442," AstraZeneca Chief
Executive Pascal Soriot said.

The total value of the deal now stands at $726 million for
up to 700,000 doses. AZD7442 is being evaluated in late-stage
trials, the company said, adding that it currently does not
expect any changes to its 2021 forecasts due to the deal.

While AstraZeneca has undergone a rollercoaster ride with
its COVID-19 vaccine, it has been working on developing new
treatments and repurposing its existing drugs to prevent and
treat coronavirus infections.

Monoclonal antibodies, such as the ones being used in
AZD7442, are synthetically manufactured copies of the human
body's natural infection-fighting proteins, and are already
being used to treat some types of cancers.

A series of issues have bogged down the drugmaker's vaccine
rollout: including pauses in trials, questions over the most
effective dosing, and supply problems. Share gains from optimism
around the cheap and easy-to-ship shot have also been decimated.

On Tuesday, the stock was up 1.5% at 7,090 pence in early
trading. At its peak in July last year, the company hit 10,120
pence.

(Reporting by Pushkala Aripaka in Bengaluru, Editing by Sherry
Jacob-Phillips and Philippa Fletcher)

More News
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.